Repligen Net Worth
Repligen Net Worth Breakdown | RGEN |
Repligen Net Worth Analysis
Repligen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Repligen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Repligen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Repligen's net worth analysis. One common approach is to calculate Repligen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Repligen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Repligen's net worth. This approach calculates the present value of Repligen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Repligen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Repligen's net worth. This involves comparing Repligen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Repligen's net worth relative to its peers.
Enterprise Value |
|
To determine if Repligen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Repligen's net worth research are outlined below:
| Repligen generated a negative expected return over the last 90 days | |
| Repligen has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 634.44 M. Net Loss for the year was (25.51 M) with profit before overhead, payroll, taxes, and interest of 332.69 M. | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Intuitive Surgicals da Vinci 5 Gaining Precision, Power and Potential |
Repligen Quarterly Good Will |
|
Repligen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Repligen. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Repligen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Repligen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Repligen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Repligen backward and forwards among themselves. Repligen's institutional investor refers to the entity that pools money to purchase Repligen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Conestoga Capital Advisors, Llc | 2025-03-31 | 980.2 K | Holocene Advisors, Lp | 2025-03-31 | 960 K | Macquarie Group Ltd | 2025-03-31 | 910 K | Amvescap Plc. | 2024-12-31 | 905.1 K | Brown Capital Management, Llc | 2025-03-31 | 864 K | Impax Asset Management Group Plc | 2025-03-31 | 804.5 K | Fmr Inc | 2025-03-31 | 732.4 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 713.6 K | Ameriprise Financial Inc | 2025-03-31 | 685 K | T. Rowe Price Associates, Inc. | 2025-03-31 | 7.6 M | Blackrock Inc | 2025-03-31 | 6.8 M |
Follow Repligen's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.42 B.Market Cap |
|
Project Repligen's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.02) | (0.02) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.01) | (0.01) |
When accessing Repligen's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Repligen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Repligen's profitability and make more informed investment decisions.
Evaluate Repligen's management efficiency
As of the 12th of June 2025, Return On Tangible Assets is likely to drop to -0.02. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Repligen's Net Tangible Assets are very stable compared to the past year. As of the 12th of June 2025, Asset Turnover is likely to grow to 0.30, while Intangible Assets are likely to drop about 242.7 M. Repligen's management efficiency ratios could be used to measure how well Repligen manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 35.27 | 37.03 | |
| Tangible Book Value Per Share | 9.72 | 10.21 | |
| Enterprise Value Over EBITDA | 97.20 | 102.06 | |
| Price Book Value Ratio | 4.08 | 3.88 | |
| Enterprise Value Multiple | 97.20 | 102.06 | |
| Price Fair Value | 4.08 | 3.88 | |
| Enterprise Value | 12.9 B | 13.5 B |
Repligen benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 11.3535 | Revenue | Quarterly Revenue Growth 0.104 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repligen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repligen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Repligen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Repligen Corporate Filings
F4 | 21st of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 15th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 24th of April 2025 Other Reports | ViewVerify | |
| 4th of April 2025 Other Reports | ViewVerify |
Repligen Earnings per Share Projection vs Actual
Repligen Corporate Management
| Christine Gebski | Senior Chromatography | Profile | |
| Kimberly Cornwell | General Counsel | Profile | |
| Dianne Heiler | Senior Sustainability | Profile | |
| James Bylund | Chief Officer | Profile | |
| Kola Otitoju | Senior Development | Profile | |
| Stephen Tingley | VP Sales | Profile | |
| Jaime Humara | Senior Marketing | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.693 | Earnings Share (0.43) | Revenue Per Share | Quarterly Revenue Growth 0.104 | Return On Assets |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.